Lexiscan

Drug Astellas Pharma US Inc
Total Payments
$677,259
Transactions
9,980
Doctors
5,096
Companies
2

Payment Trends by Year

Year Amount Transactions Doctors
2023 $38,897 159 141
2022 $106,673 1,240 925
2021 $17.52 1 1
2017 $531,672 8,580 4,342

Payments by Nature

Nature of Payment Amount Transactions Share
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $286,560 97 42.3%
Food and Beverage $187,145 9,691 27.6%
Space rental or facility fees (teaching hospital only) $74,045 50 10.9%
Consulting Fee $66,199 13 9.8%
Unspecified $35,011 10 5.2%
Travel and Lodging $28,299 119 4.2%

Payments by Type

General
$642,248
9,970 transactions
Research
$35,011
10 transactions

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
Clinical Trial of the Safety and Efficacy of Regadenoson for Moderate to Severe COVID-19 in Adult Patients Astellas Pharma Global Development $29,920 0
Retrospective Analysis of Patient Outcomes and Clinical Characteristics in Recovered COVID-19 Patients with Pharmacological Stress Tests in the United States Astellas Pharma Global Development $5,091 1

Top Doctors Receiving Payments for Lexiscan — Page 203

Doctor Specialty Location Total Records
, MD, MSC Clinical Cardiac Electrophysiology Zephyrhills, FL $10.69 1
, M.D Cardiovascular Disease Columbia, SC $10.68 1
, M.D Advanced Heart Failure and Transplant Cardiology Columbia, SC $10.68 1
, M.D Internal Medicine Skowhegan, ME $10.64 1
, MD Interventional Cardiology South Charleston, WV $10.64 1
, MD Hospitalist Skowhegan, ME $10.64 1
, MD Internal Medicine Richmond, IN $10.62 1
, M.D Interventional Cardiology Richmond, IN $10.62 1
, MD Pediatrics Arcadia, CA $10.62 1
, M.D Interventional Cardiology Clairton, PA $10.61 1
, M.D Cardiovascular Disease Monongahela, PA $10.61 1
, M.D Specialist Cincinnati, OH $10.58 1
, M.D Cardiovascular Disease Venice, FL $10.57 1
, M.D Cardiovascular Disease Venice, FL $10.57 1
Kuchela Reddy Riverdale, GA $10.52 1
, MD Cardiovascular Disease Tucson, AZ $10.50 1
, MD Internal Medicine Michigan City, IN $10.47 1
, MD Cardiovascular Disease Danville, KY $10.43 1
, MD Cardiovascular Disease Danville, KY $10.43 1
, M.D Cardiovascular Disease Danville, KY $10.43 1
, DO Cardiovascular Disease Danville, KY $10.43 1
, MD Cardiovascular Disease Danville, KY $10.43 1
, MD Diagnostic Radiology Batavia, OH $10.42 1
, M.D Internal Medicine Cincinnati, OH $10.42 1
, MD Internal Medicine Bloomington, IN $10.40 1

About Lexiscan

Lexiscan is a drug associated with $677,259 in payments to 5,096 healthcare providers, recorded across 9,980 transactions in the CMS Open Payments database. The primary manufacturer is Astellas Pharma US Inc.

Payment data is available from 2017 to 2023. In 2023, $38,897 was paid across 159 transactions to 141 doctors.

The most common payment nature for Lexiscan is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($286,560, 42.3% of total).

Lexiscan is associated with 2 research studies, including "Clinical Trial of the Safety and Efficacy of Regadenoson for Moderate to Severe COVID-19 in Adult Patients" ($29,920).